FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920797532> ?p ?o ?g. }

• W2920797532 endingPage "1427" @default.
• W2920797532 startingPage "1417" @default.
• W2920797532 abstract "Background Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes hydrochloric acid from the gastrointestinal lumen, unlike current oral sodium bicarbonate therapy for metabolic acidosis that only neutralises accumulated acid. We assessed the efficacy and safety of veverimer as a treatment for metabolic acidosis in patients with chronic kidney disease. Methods We did a multicentre, parallel, randomised, double-blind, placebo-controlled study at 37 sites (hospitals and specialty clinics) in Bulgaria, Croatia, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA. Eligible participants were patients aged 18–85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20–40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12–20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation code with balanced permuted blocks (block size of seven) and stratified by baseline bicarbonate (≤18 mmol/L vs >18 mmol/L). Patients and investigators were masked to treatment allocation; however, because the appearance of placebo differed from veverimer, a non-masked site staff member who had no other role in the study dispensed, prepared, and supervised dosing of the study drugs. The composite primary efficacy endpoint was the difference (veverimer–placebo) in the proportion of patients achieving at week 12 either an increase of 4 mmol/L or more from baseline in serum bicarbonate concentration or serum bicarbonate in the normal range of 22–29 mmol/L, assessed in the modified intention-to-treat population (all patients with a baseline and at least one post-baseline serum bicarbonate value). Patients fasted for at least 4 h (consuming only water) before measurements of bicarbonate. Safety was assessed in all patients who received any amount of study drug. This trial is registered with ClinicalTrials.gov, number NCT03317444. Findings Between Sept 26, 2017, and Feb 9, 2018, we randomly assigned 124 participants to veverimer and 93 to placebo. The composite primary endpoint was met by 71 (59%) of 120 patients in the veverimer group versus 20 (22%) of 89 patients in the placebo group (a difference of 37%, 95% CI 23–49; p<0·0001). The most common body system in which adverse events in the veverimer group occurred was gastrointestinal; of these, non-treatment limiting diarrhoea was the most common event (11 [9%] vs three [3%] in the veverimer and placebo groups, respectively). The most common treatment-related adverse events were gastrointestinal (diarrhoea, flatulence, nausea, and constipation) occurring in 16 (13%) patients with veverimer and five (5%) patients with placebo. Two deaths occurred during the study, both in the placebo group (unstable angina and pneumonia). Interpretation Veverimer effectively and safely corrected metabolic acidosis. Longer-term studies are warranted to assess the effects of veverimer on physical functioning and to assess other deleterious consequences of metabolic acidosis including progression of chronic kidney disease and bone health. Funding Tricida. Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes hydrochloric acid from the gastrointestinal lumen, unlike current oral sodium bicarbonate therapy for metabolic acidosis that only neutralises accumulated acid. We assessed the efficacy and safety of veverimer as a treatment for metabolic acidosis in patients with chronic kidney disease. We did a multicentre, parallel, randomised, double-blind, placebo-controlled study at 37 sites (hospitals and specialty clinics) in Bulgaria, Croatia, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA. Eligible participants were patients aged 18–85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20–40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12–20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation code with balanced permuted blocks (block size of seven) and stratified by baseline bicarbonate (≤18 mmol/L vs >18 mmol/L). Patients and investigators were masked to treatment allocation; however, because the appearance of placebo differed from veverimer, a non-masked site staff member who had no other role in the study dispensed, prepared, and supervised dosing of the study drugs. The composite primary efficacy endpoint was the difference (veverimer–placebo) in the proportion of patients achieving at week 12 either an increase of 4 mmol/L or more from baseline in serum bicarbonate concentration or serum bicarbonate in the normal range of 22–29 mmol/L, assessed in the modified intention-to-treat population (all patients with a baseline and at least one post-baseline serum bicarbonate value). Patients fasted for at least 4 h (consuming only water) before measurements of bicarbonate. Safety was assessed in all patients who received any amount of study drug. This trial is registered with ClinicalTrials.gov, number NCT03317444. Between Sept 26, 2017, and Feb 9, 2018, we randomly assigned 124 participants to veverimer and 93 to placebo. The composite primary endpoint was met by 71 (59%) of 120 patients in the veverimer group versus 20 (22%) of 89 patients in the placebo group (a difference of 37%, 95% CI 23–49; p<0·0001). The most common body system in which adverse events in the veverimer group occurred was gastrointestinal; of these, non-treatment limiting diarrhoea was the most common event (11 [9%] vs three [3%] in the veverimer and placebo groups, respectively). The most common treatment-related adverse events were gastrointestinal (diarrhoea, flatulence, nausea, and constipation) occurring in 16 (13%) patients with veverimer and five (5%) patients with placebo. Two deaths occurred during the study, both in the placebo group (unstable angina and pneumonia). Veverimer effectively and safely corrected metabolic acidosis. Longer-term studies are warranted to assess the effects of veverimer on physical functioning and to assess other deleterious consequences of metabolic acidosis including progression of chronic kidney disease and bone health." @default.
• W2920797532 created "2019-03-22" @default.
• W2920797532 creator A5010386833 @default.
• W2920797532 creator A5019935894 @default.
• W2920797532 creator A5042762794 @default.
• W2920797532 creator A5056005655 @default.
• W2920797532 creator A5058965585 @default.
• W2920797532 creator A5076583644 @default.
• W2920797532 creator A5089363439 @default.
• W2920797532 creator A5091483213 @default.
• W2920797532 date "2019-04-01" @default.
• W2920797532 modified "2023-10-01" @default.
• W2920797532 title "Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial" @default.
• W2920797532 cites W1983659087 @default.
• W2920797532 cites W1984423173 @default.
• W2920797532 cites W1994174181 @default.
• W2920797532 cites W2001920176 @default.
• W2920797532 cites W2010550213 @default.
• W2920797532 cites W2012979540 @default.
• W2920797532 cites W2014046186 @default.
• W2920797532 cites W2026719046 @default.
• W2920797532 cites W2042680317 @default.
• W2920797532 cites W2054323843 @default.
• W2920797532 cites W2060886633 @default.
• W2920797532 cites W2096523173 @default.
• W2920797532 cites W2106880819 @default.
• W2920797532 cites W2108629029 @default.
• W2920797532 cites W2115257346 @default.
• W2920797532 cites W2117650285 @default.
• W2920797532 cites W2146854188 @default.
• W2920797532 cites W2151456801 @default.
• W2920797532 cites W2163540069 @default.
• W2920797532 cites W2165817472 @default.
• W2920797532 cites W2277103284 @default.
• W2920797532 cites W2316138036 @default.
• W2920797532 cites W2605075104 @default.
• W2920797532 cites W2761903250 @default.
• W2920797532 cites W2765955869 @default.
• W2920797532 cites W2902701987 @default.
• W2920797532 cites W2908564122 @default.
• W2920797532 cites W3026731266 @default.
• W2920797532 doi "https://doi.org/10.1016/s0140-6736(18)32562-5" @default.
• W2920797532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30857647" @default.
• W2920797532 hasPublicationYear "2019" @default.
• W2920797532 type Work @default.
• W2920797532 sameAs 2920797532 @default.
• W2920797532 citedByCount "58" @default.
• W2920797532 countsByYear W29207975322019 @default.
• W2920797532 countsByYear W29207975322020 @default.
• W2920797532 countsByYear W29207975322021 @default.
• W2920797532 countsByYear W29207975322022 @default.
• W2920797532 countsByYear W29207975322023 @default.
• W2920797532 crossrefType "journal-article" @default.
• W2920797532 hasAuthorship W2920797532A5010386833 @default.
• W2920797532 hasAuthorship W2920797532A5019935894 @default.
• W2920797532 hasAuthorship W2920797532A5042762794 @default.
• W2920797532 hasAuthorship W2920797532A5056005655 @default.
• W2920797532 hasAuthorship W2920797532A5058965585 @default.
• W2920797532 hasAuthorship W2920797532A5076583644 @default.
• W2920797532 hasAuthorship W2920797532A5089363439 @default.
• W2920797532 hasAuthorship W2920797532A5091483213 @default.
• W2920797532 hasConcept C126322002 @default.
• W2920797532 hasConcept C142724271 @default.
• W2920797532 hasConcept C204787440 @default.
• W2920797532 hasConcept C27081682 @default.
• W2920797532 hasConcept C2778653478 @default.
• W2920797532 hasConcept C2779134260 @default.
• W2920797532 hasConcept C2779246250 @default.
• W2920797532 hasConcept C2991744798 @default.
• W2920797532 hasConcept C71924100 @default.
• W2920797532 hasConceptScore W2920797532C126322002 @default.
• W2920797532 hasConceptScore W2920797532C142724271 @default.
• W2920797532 hasConceptScore W2920797532C204787440 @default.
• W2920797532 hasConceptScore W2920797532C27081682 @default.
• W2920797532 hasConceptScore W2920797532C2778653478 @default.
• W2920797532 hasConceptScore W2920797532C2779134260 @default.
• W2920797532 hasConceptScore W2920797532C2779246250 @default.
• W2920797532 hasConceptScore W2920797532C2991744798 @default.
• W2920797532 hasConceptScore W2920797532C71924100 @default.
• W2920797532 hasIssue "10179" @default.
• W2920797532 hasLocation W29207975321 @default.
• W2920797532 hasLocation W29207975322 @default.
• W2920797532 hasOpenAccess W2920797532 @default.
• W2920797532 hasPrimaryLocation W29207975321 @default.
• W2920797532 hasRelatedWork W2412727020 @default.
• W2920797532 hasRelatedWork W2414115992 @default.
• W2920797532 hasRelatedWork W2468589341 @default.
• W2920797532 hasRelatedWork W2913074078 @default.
• W2920797532 hasRelatedWork W2920090081 @default.
• W2920797532 hasRelatedWork W2981884515 @default.
• W2920797532 hasRelatedWork W3003571257 @default.
• W2920797532 hasRelatedWork W4233016836 @default.
• W2920797532 hasRelatedWork W4236983578 @default.
• W2920797532 hasRelatedWork W1556208436 @default.
• W2920797532 hasVolume "393" @default.
• W2920797532 isParatext "false" @default.
• W2920797532 isRetracted "false" @default.
• W2920797532 magId "2920797532" @default.

• next